What is another name for acalabrutinib?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Alternative Names for Acalabrutinib

Acalabrutinib is marketed under the brand name Calquence®. 1, 2

Brand and Chemical Names

  • Brand name: Calquence® 1, 2
  • Chemical name: 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide (2Z)-2-butenedioic acid hydrate 1
  • Salt form: Acalabrutinib maleate 1
  • Development code: ACP-196 3

Active Metabolite

  • Major active metabolite: ACP-5862 (also known as M27), which is a pyrrolidine ring-opened ketone/amide derivative that contributes to the clinical efficacy of acalabrutinib 4
  • ACP-5862 is formed through CYP3A4-mediated metabolism and demonstrates potent and selective covalent BTK inhibition, with only twofold lower potency than the parent compound 4

Drug Classification

  • Pharmacological class: Bruton tyrosine kinase (BTK) inhibitor 1, 3
  • Generation: Second-generation BTK inhibitor, designed to be more selective and potent than the first-generation agent ibrutinib 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.